– USA, CA – DermTech, Inc. (NASDAQ: DMTK), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Monica Tellado, SVP, Finance at Gilead Sciences to its Board of Directors.
“We are so fortunate to welcome Monica to our Board of Directors,” said Board Chairman, Matt Posard. “As the company continues to scale for growth and expansion, Monica brings critical perspectives on commercializing new products and driving operational excellence to support business growth and efficiencies.”
About Monica Tellado
Monica’s experience includes 18 years at Gilead Sciences, in roles of progressive leadership responsibility up to and including her current role as SVP, Finance. She’s been responsible for the U.S. and Latin American commercial markets, led preparations to enter new markets and launch new products within Gilead’s HIV, Liver, Cardiopulmonary, and Oncology business units, and was responsible for the U.S. Liver Disease business unit including a P&L of nearly $2 billion. In her current role as SVP, Finance, Monica oversees global financial planning and analysis as well as investor relations.
“It is a great pleasure to join the DermTech Board of Directors at such an exciting and important point in the Company’s history,” said Ms. Tellado. “I look forward to contributing to DermTech’s vision to lead the genomics revolution in skin health, particularly as we step into this crucial next phase of growth.”
Monica received a Master of Business Administration from Carnegie Mellon University.
About DermTech:
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, democratize access to high-quality dermatology care, and improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
For more information: https://dermtech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
